Navigation Links
Optimer Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results
Date:3/10/2011

ed clinical cure vs. 90.6% for Vancocin®.  Importantly, fidaxomicin also showed significantly lower recurrence rates (p=0.002) and higher global cure rates (p<0.001) compared to Vancocin.  

Scheduled Conference CallThe Company will host both a conference call and webcast to discuss the fourth quarter and full year 2010 financial results and to provide a corporate update today, Thursday, March 10, 2011 at 4:30 p.m. Eastern time (1:30 p.m. Pacific time).

The conference call may be accessed by dialing (877) 280-7280 for domestic callers and (678) 825-8232 for international callers.  Please specify to the operator that you would like to join the "Optimer Earnings Call." The conference call will be webcast live under the Investors section of Optimer's website at www.optimerpharma.com, where it will be archived for 30 days following the call.About Optimer PharmaceuticalsOptimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing hospital specialty products to treat serious infections and address unmet medical needs. Optimer has two anti-infective product candidates in development, fidaxomicin and Pruvel™ (prulifloxacin). Fidaxomicin is a narrow spectrum antibiotic being developed for the treatment of Clostridium difficile infection (CDI). The FDA granted the Company's request for six-month Priority Review of fidaxomicin, and has assigned a Prescription Drug User Fee Act (PDUFA) goal date of May 30, 2011. The Company also filed a MAA with the European Medicines Agency (EMA) for fidaxomicin. Pruvel™ is a prodrug in the fluoroquinolone class of antibiotics being developed as a treatment for infectious diarrhea. Additional information can be found at http://www.optimerpharma.com.

Forward-looking StatementsStatements included in this press release that are not a
'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Optimer Pharmaceuticals Receives Production Patent for Lead Product Candidate Fidaxomicin
2. Optimer Pharmaceuticals Presents Results From Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection
3. Data From Optimers Second Phase 3 Study of Prulifloxacin Presented at Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
4. Optimer Announces Presentation of Additional Data From Fidaxomicin Phase 3 Study for the Treatment of Clostridium Difficile Infection (CDI)
5. Optimer Pharmaceuticals to Present at the 21st Annual Piper Jaffray Health Care Conference
6. Optimer Pharmaceuticals to Present at the 28th Annual J.P. Morgan Healthcare Conference
7. Optimer Pharmaceuticals Fidaxomicin Marketing Authorization Application Accepted for Review by European Medicines Agency
8. Optimer Pharmaceuticals to Present at September 2010 Investor Conferences
9. Optimer Pharmaceuticals Announces Presentations of Additional Fidaxomicin Phase 3 Data at Upcoming ICAAC Annual Meeting
10. Optimer Pharmaceuticals Announces Combined Data From Fidaxomicin Phase 3 Trials for the Treatment of Clostridium difficile Infection (CDI) Presented at IDSA
11. Optimer Pharmaceuticals to Host Investor and Analyst Event on November 18
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... Md. , Nov. 21, 2014  The University ... will host the ceremonial groundbreaking of the new A. ... Park. The new building will cultivate transformative new engineering ... Taking place at 10:00 a.m. on November ... the Paint Branch Parking Lot, adjacent to the Jeong ...
(Date:11/21/2014)... 2014   Rock Creek Pharmaceuticals, Inc., (NASDAQ: ... scheduled to present at the Biotech Showcase™ 2015 taking ... on January 12-14, 2015. Michael ... Creek Pharmaceuticals, will present preclinical and clinical data for ... anti-inflammatory pharmacological characteristics. Dr. Mullan will outline the Company,s ...
(Date:11/21/2014)... 21, 2014  PTC Therapeutics, Inc. (NASDAQ: PTCT ... Technology Award for Vision, Innovation, and Leadership has been awarded ... This award recognizes an individual who has had a significant ... for several decades. "I am honored ... Stuart Peltz , Ph.D., CEO of PTC Therapeutics, Inc. "When ...
Breaking Medicine Technology:University of Maryland Breaks Ground for A. James Clark Hall 2University of Maryland Breaks Ground for A. James Clark Hall 3University of Maryland Breaks Ground for A. James Clark Hall 4Rock Creek Pharmaceuticals to Present at the Biotech Showcase 2015 2Rock Creek Pharmaceuticals to Present at the Biotech Showcase 2015 3Rock Creek Pharmaceuticals to Present at the Biotech Showcase 2015 4PTC Therapeutics Announces CEO, Dr. Stuart Peltz Recipient of The New Jersey Technology Council's 2014 Legend of Technology Award 2PTC Therapeutics Announces CEO, Dr. Stuart Peltz Recipient of The New Jersey Technology Council's 2014 Legend of Technology Award 3
... (NYSE: HRC ) today announced the appointment ... Chain.  Currently serving as General Manager for Global Lean ... on September 13, 2010.  In addition to his responsibilities ... will be responsible for all aspects of Hill-Rom,s global ...
... Aug. 31 Amedica Corporation, a spinal and ... silicon nitride (SiN) ceramic technologies, announced today that ... 7,776,085 B2, covering an improved knee implant prosthesis ... articulation with natural or prosthetic (resurfaced) femoral surfaces. ...
Cached Medicine Technology:Hill-Rom Appoints Scott Jeffers as Senior Vice President, Global Supply Chain 2Amedica® Receives Patent for Knee Prosthesis With Monoblock Silicon Nitride Ceramic Tibial Component 2Amedica® Receives Patent for Knee Prosthesis With Monoblock Silicon Nitride Ceramic Tibial Component 3
(Date:11/24/2014)... 24, 2014 SWAccessControl.com has recently ... a matter of fact, the company is a leading online ... new magnetic locks are available at discounted prices, up to ... range of magnetic locks. This time, all of our items ... at home and abroad, so I have confidence in our ...
(Date:11/24/2014)... and Philadelphia, PA (PRWEB) November 24, 2014 ... of care coordination and disease management services to ... chosen to implement Essette’s Medical Management software suite. ... Essette SaaS platform in a program to reduce ... suite includes Population Health Management, Care Management, Utilization ...
(Date:11/23/2014)... Dallas, TX (PRWEB) November 24, 2014 ... Trials Review, H2, 2014" provides data on the ... information and data relating to the clinical trials ... trial numbers and their recruitment status as per ... The databook offers a preliminary coverage of disease ...
(Date:11/23/2014)... November 24, 2014 Tbdress.com has ... available online on Nov. 28, 2014. The special offer will ... , Tbdress.com is one of the world’s largest women’s dresses ... and colors. People can enjoy great discounts on that day: ... enjoy free delivery (for orders above $89). , People can ...
(Date:11/23/2014)... (HealthDay News) -- The holidays can be a challenge ... can trigger major meltdowns, an expert says. "Holidays ... circumstances, but when you have children with special needs, ... therapy professor at University of the Sciences in Philadelphia, ... to let your hosts or visitors know what special ...
Breaking Medicine News(10 mins):Health News:SWAccessControl.com Is Happy To Release New Range Of Magnetic Locks 2Health News:ReAdmission Solutions, LLC Selects Essette 2Health News:Aspergillosis Pipeline and Clinical Trials Market (Compnies and Drugs) Review H2 2014 Report at ReportsnReports.com 2Health News:Aspergillosis Pipeline and Clinical Trials Market (Compnies and Drugs) Review H2 2014 Report at ReportsnReports.com 3Health News:Aspergillosis Pipeline and Clinical Trials Market (Compnies and Drugs) Review H2 2014 Report at ReportsnReports.com 4Health News:Tbdress.com Special Friday Shoes Sales Online Now 2Health News:Holidays Can Be Sensory Overload for Kids With Autism 2
... that have only about 20 nucleotides and do not code ... binding to target messenger RNAs the instructions for protein ... cancer, the production of some miRNAs is often reduced or ... cancer-promoting genes. A key molecule in the development ...
... Thomas J. Watkins Professor of Obstetrics and Gynecology at ... Presidential Award for Excellence in Science, Mathematics and Engineering ... Monday, Dec. 12. The award was for ... Program for High School Girls and Beyond. The program ...
... 16 (HealthDay News) -- Men often have difficulty accurately reading a ... In what should come as no surprise to any woman who,s ... tends to think all women want him, while other guys just ... included 96 male and 103 female U.S. college undergraduates who took ...
... Europe provide plentiful food in summer, finding enough to eat ... avoid the problem by hibernating but this survival strategy is ... of some bears, large mammals remain fully awake throughout the ... with the comparative scarcity of food. Red deer, for ...
... for cystic fibrosis produced sustained improvement in lung function ... study. Along with the treatment,s efficacy and good safety ... treatment may improve adherence with therapy in these patients. ... Pharmaxis Limited, 318 patients were randomized to treatment with ...
... antiretroviral therapy (ART) appears preferable to deferring treatment, according ... of Infectious Diseases and now available online. Although ... unproven, the findings support growing evidence favoring earlier ART ... of Wisconsin in Milwaukee, led a team of researchers ...
Cached Medicine News:Health News:No brakes on breast cancer cells 2Health News:Northwestern scientist gets mentoring award at White House 2Health News:Northwestern scientist gets mentoring award at White House 3Health News:Men Often Misread Women's Sexual Cues: Study 2Health News:Winter diets? The secret is to chill the extremities 2Health News:Winter diets? The secret is to chill the extremities 3Health News:Long-term inhaled dry powder mannitol improves lung function in CF 2Health News:Study suggests early ART in recently HIV-infected patients preferable to delayed treatment 2
Freer elevator, double end, 7 1/4", S/B....
... Surgifoam* absorbable gelatin sponge, U.S.P. is ... absorbable sponge intended for hemostatic use ... The sponge is off-white and porous ... to hemostasis, highly favorable surgeon preference ...
8 mm diameter curved probes with suture eyes just back of blunt ends. Stainless steel. Round knurled handle with polished finish. Overall length: 5.6 inches....
Yag Laser System SYL is compact and light-weight. It is CE Mark approved according to MDD....
Medicine Products: